

# Jeonghee Cho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9299036/publications.pdf>

Version: 2024-02-01

30  
papers

4,875  
citations

361045

20  
h-index

454577

30  
g-index

30  
all docs

30  
docs citations

30  
times ranked

9273  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 1205.	1.7	25
2	Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 589.	1.7	32
3	Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. <i>International Journal of Cancer</i> , 2020, 146, 2194-2200.	2.3	20
4	Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. <i>BMB Reports</i> , 2020, 53, 133-141.	1.1	6
5	Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. <i>Cells</i> , 2019, 8, 878.	1.8	17
6	Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung cancer derived EGFR mutants. <i>International Journal of Cancer</i> , 2018, 143, 679-685.	2.3	8
7	Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 710-714.	1.0	3
8	Analogues of Dehydroacetic Acid as Selective and Potent Agonists of an Ectopic Odorant Receptor through a Combination of Hydrophilic and Hydrophobic Interactions. <i>ChemMedChem</i> , 2017, 12, 477-482.	1.6	4
9	Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal cancers. <i>Cancer Management and Research</i> , 2017, Volume 9, 581-589.	0.9	19
10	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	0.8	23
11	Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 6538-6551.	0.8	29
12	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016, 7, 13797-13809.	0.8	7
13	Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 703-711.	3.6	72
14	Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. <i>Oncotarget</i> , 2015, 6, 8839-8850.	0.8	12
15	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	1.9	34
16	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. <i>Molecular Cancer</i> , 2014, 13, 141.	7.9	24
17	Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. <i>Cancer Research</i> , 2013, 73, 6770-6779.	0.4	87
18	Identification of ROS1 rearrangement in gastric adenocarcinoma. <i>Cancer</i> , 2013, 119, 1627-1635.	2.0	108

#	ARTICLE	IF	CITATIONS
19	Integrated cisomic and expression analysis of amplified <i>NKX2-1</i> in lung adenocarcinoma identifies <i>LMO3</i> as a functional transcriptional target. <i>Genes and Development</i> , 2013, 27, 197-210.	2.7	61
20	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of <i>ERBB2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14476-14481.	3.3	246
21	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. <i>Cell</i> , 2012, 150, 1107-1120.	13.5	1,591
22	Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 78-89.	7.7	455
23	Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies. <i>Cancer Research</i> , 2011, 71, 7587-7596.	0.4	70
24	Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e20351.	1.1	338
25	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 2042-2050.	1.5	78
26	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007, 450, 893-898.	13.7	1,020
27	Tpl2/Cot Signals Activate ERK, JNK, and NF- $\kappa$ B in a Cell-type and Stimulus-specific Manner. <i>Journal of Biological Chemistry</i> , 2005, 280, 23748-23757.	1.6	127
28	Phosphorylation at Thr-290 regulates Tpl2 binding to NF- $\kappa$ B1/p105 and Tpl2 activation and degradation by lipopolysaccharide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2350-2355.	3.3	64
29	Tpl2 (Tumor Progression Locus 2) Phosphorylation at Thr290 Is Induced by Lipopolysaccharide via an $\text{I}\kappa\text{B}$ Kinase- $\text{I}\kappa\text{B}$ -dependent Pathway and Is Required for Tpl2 Activation by External Signals. <i>Journal of Biological Chemistry</i> , 2005, 280, 20442-20448.	1.6	50
30	Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. <i>EMBO Journal</i> , 2002, 21, 4831-4840.	3.5	245